Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GHTF Takes Prospective Approach To Address Innovative Medical Technology

This article was originally published in The Silver Sheet

Executive Summary

GHTF PLAN FOR NEW AND EMERGING MEDICAL TECHNOLOGY seeks to create a mechanism for developing a harmonized regulatory approach for dealing with innovative products to avoid the proliferation of country-specific guidelines. During the ninth Global Harmonization Task Force meeting in Singapore, the GHTF Steering Committee outlined a proposed plan for taking a prospective approach to emerging technology – part of a series of "strategic goals" designed to guide the direction of the task force over the next few years. Participants and at the conference discussed at length the extensive challenges for regulators and industry posed by the coming flood of new medical technology and warned that without immediate action, innovation could be stifled

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel